GSK-Theravance's Breo wins FDA approval for COPD

05/12/2013 | Reuters

GlaxoSmithKline and Theravance obtained FDA approval to market Breo, a combination of the new beta agonist vilanterol and fluticasone furoate, a corticosteroid, as a treatment for chronic obstructive pulmonary disease. Due to risk of asthma-related death, the inhaled treatment will carry a boxed warning.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC